Lessons from the Meningitis Vaccine Project
| Autor: | Mamoudou Harouna Djingarey, F. Marc LaForce, Marie-Pierre Preziosi, Simonetta Viviani |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Economic growth medicine.medical_specialty 030106 microbiology Immunology Meningococcal Infections Meningococcal Vaccines Meningitis Meningococcal World Health Organization World health 03 medical and health sciences 0302 clinical medicine Neisseria meningitidis Serogroup A Virology Drug Discovery Humans Medicine 030212 general & internal medicine Africa South of the Sahara Life span Immunization Programs business.industry Health Policy Public health Meningitis Vaccine Project medicine.disease Scale (social sciences) General partnership Molecular Medicine business Meningitis |
| Zdroj: | Viral Immunology. 31:109-113 |
| ISSN: | 1557-8976 0882-8245 |
| Popis: | From 2001 to 2017 the Meningitis Vaccine Project (MVP), a Gates Foundation funded partnership between PATH and the World Health Organization (WHO), successfully developed, tested, licensed, and introduced an affordable new Group A meningococcal conjugate vaccine, MenAfriVac, in sub-Saharan Africa. The vaccine was well received, and from 2010 to 2016, over 260 million Africans have received a dose of the vaccine in campaigns largely directed at 1–29-year olds. The public health impact has been dramatic with the elimination of Group A meningococcal infections wherever the vaccine has been used at public health scale. Over its 16-year life span, MVP faced many challenges, and lessons were learned that may be of interest to other groups seeking to develop vaccine products for resource-poor countries. We have chosen to highlight six elements that were keys to the success of the project: (a) country and African regional engagement during all phases of the project; (b) the evolution of the WHO/PATH partnership; (c) funding the introduction of MenAfriVac in meningitis belt countries; (d) regulatory challenges; (e) clinical trials in Africa and India; and (f ) the realities of vaccine development partnerships. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|